Incidence of Steroid-induced Diabetes in COVID-19 patients

Rana, Manish; Siddiqui, Mujtaba Hasan; Raza, Sitara; Tehreem, Kinza; Mahmood, Maria; Javed, Muhammad; Qayyum, Mehwish; Hafeez, MM

doi:10.53350/pjmhs2115102595

Cited by 4 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For severe COVID-19, glucocorticoids are indicated for lung disease, which may, in turn, increase the risk of diabetes mellitus (12,33,34). For example, in an Indian study, of the 31 individuals who had been treated with steroids while on admission for COVID-19, eleven (35.5%) went on to develop new-onset diabetes three months later (12).…”

Section: Discussionmentioning

confidence: 99%

The prevalence of pre-diabetes and diabetes in people with and without past history of COVID-19 in northeastern Nigeria

Stephen,

Tyndal,

Hsu

et al. 2024

Preprint

View full text Add to dashboard Cite

Background An increased risk of diabetes mellitus (DM) after COVID-19 has been reported in the United States, Europe, and Asia. The burden of COVID-related DM has not been described in Africa, where the overall risk of DM has been increasing rapidly. Our objective was to compare the prevalence of pre-DM and DM in Nigerian individuals with a history of COVID-19 to individuals without known COVID-19 infection. Methods We identified 256 individuals with a past medical history of COVID-19 with no history of pre-DM or DM and 256 individuals without a history of COVID-19 or pre-DM/DM. Participants were categorized as pre-DM (fasting capillary glucose 100–125 mg/dL) or DM (fasting capillary glucose ≥ 126 mg/dL). We used multivariate multinomial logistic regression to determine the odds of pre-DM and DM in those with and without a history of COVID-19 after adjustment for age, gender, the presence of hypertension, physical activity, central adiposity, and family history of DM. Results Compared to the control group, those with a history of COVID-19 had a similar median age (38 vs 40 years, p = 0.84), had a higher proportion of men (63% vs 49%), and had a lower prevalence of central adiposity (waist: hip ratio ≥ 0.90 for males and WHR ≥ 0.85 for females) (48% vs 56.3%, p = 0.06). Of the 256 with a history of COVID-19, 44 (17%) required inpatient care. The median (interquartile range) time interval between COVID-19 diagnosis and the glycaemic assessment was 19 (14, 24) months. Pre-DM prevalence was 27% in the post-COVID-19 group and 4% in the control group, whereas the prevalence of DM was 7% in the post-COVID-19 group and 2% in the control group. After multivariable adjustment, the odds of pre-DM were 8.12 (95% confidence interval (CI): 33.98, 16.58; p < 0.001) higher, and the odds of DM were 3.97 (95% CI: 1.16, 13.63) higher in those with a history of COVID-19 compared to controls. Conclusion Previous COVID-19 was found to be a risk factor for prevalent pre-diabetes and diabetes mellitus in Nigeria. More intensive screening for DM in those with a history of COVID-19 should be considered.

show abstract

Section: Discussionmentioning

confidence: 99%

The prevalence of pre-diabetes and diabetes in people with and without past history of COVID-19 in northeastern Nigeria

Stephen,

Tyndal,

Hsu

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…29 Dos tercios de los pacientes presentaron glicemia en rango de diabetes, lo cual es alto si se compara con lo reportado por Liu et al, quienes hallaron 32,3% de hiperglicemia inducida por corticoides (p=0,003) y 18,6% de diabetes (p=0,002) 30 , o lo reportado por Rana et al, quienes hallaron una incidencia de 15,65% de diabetes. 31 Se ha informado que el uso de corticoides duplica y hasta triplica el riesgo de presentar diabetes mellitus y se asocia a mayor requerimiento de fármacos antidiabéticos. 32 La glucosa al día 20 fue de 14 mg/dl más con dexametasona; si bien es cierto no es significativa respecto a metilprednisolona (p=0,17), tendría su explicación por el tiempo de acción de la dexametasona ya que se ha descrito que, al ser de larga acción, la resolución de la hiperglicemia ocurre a las 24 a 36 horas.…”

Section: Discussionunclassified

Hiperglicemia asociada al uso de corticoides en pacientes con COVID-19

Camacho-Saavedra,

Ramal-Aguilar,

Casamayor-Quipuzcoa

2023

spmi

View full text Add to dashboard Cite

En la enfermedad por coronavirus, los corticoides pueden modular el daño pulmonar mediado por inflamación, logrando reducir la insuficiencia respiratoria y muerte; entre sus reacciones adversas provocan hiperglicemia. Objetivo: identificar la frecuencia y magnitud del incremento de glucosa en pacientes con COVID-19 que recibieron corticoides, Método: se realizó un estudio retrospectivo en pacientes adultos admitidos al servicio de hospitalización COVID-19del Hospital de Alta Complejidad Virgen de la Puerta, Red Asistencial La Libertad de EsSalud, Perú, de abril a setiembre del 2020. Se identificó la glucosa al inicio y luego a partir del quinto día de la exposición a corticoides. Resultados: Se incluyó 103 pacientes con edad promedio de 62,12 años, 66% varones. 49,5 % recibieron dexametasona, 49,5% metilprednisolona y 1% hidrocortisona. La glicemia promedio al ingreso fue 109,34 ± 12,89 mg/dl; al día 5 fue 131,61 ±17,66; al día 10 fue 128,10 ± 25,78 mg/ dl; al día 20 fue 124,96 ± 27,32 mg/dl; y, al día 30 fue 115,3 ± 29,43 mg/dl. El 63,11% de pacientes presentó glicemiamayor a 125 mg/dl al día 5 de tratamiento. Conclusión: los niveles de glucosa aumentaron significativamente del día 5 al día 20 del tratamiento con corticoidesen pacientes hospitalizados por COVID-19 y el 63% presentó niveles de glucosa en rango de diabetes mellitus.

show abstract

“…Of all patients with a history of steroid use, only 33.3% have severe degrees of COVID-19. A higher prevalence was found byRana dkk., (2021), where the majority of a history of steroid use was found in 15.7% of cases [21] Comorbid illnesses are widely recognized as risk factors for COVID-19. This study found that 71.4% had comorbid diseases.…”

Section: International Journal Of Scientific Advances Issn: 2708-7972mentioning

confidence: 99%

Hyperglycemia and Obesity as Risk Factors for Severe Covid-19

Nugraha¹,

Ngurah²,

Sajinadiyasa³

et al. 2023

International Journal of Scientific Advances

View full text Add to dashboard Cite

Background: Obesity and hyperglycemia are common in patients with COVID-19 and are associated with an aggravating risk of COVID-19. This study assesses hyperglycemia and obesity as risk factors for developing severe COVID-19. Method: Analytical observational research with the design used is a matched case-control study. This study divided subjects into two groups according to the dependent variable category of severe COVID-19 as a case and not as severe as a control group. In each group, a history of hyperglycemia and obesity was traced. The analysis includes descriptive tests, bivariate with Chi-Square and multivariate with linear logistic regression using Statistical Product and Service Solutions (SPSS) 26. Result: 126 subjects divided into two groups with 63 subjects each. By age, the COVID-19 group was found to be severe, with an average of 57.9±12.731, and the COVID-19 group was not severe, with an average of 57.53±12.589. Hyperglycemia was associated with severe COVID-19 with a p-result of 0.000 (OR 11.8; CI 95% 3.819-36.456). Obesity was associated with severe COVID-19 with a result of p 0.001 (OR 4.6; CI 95% 1.8 – 11.756). Another covariant factor related to the severity of COVID-19 is Diabetes mellitus (OR: 4.6; CI 95% 2.148–10.137; p=0.028)cardiovascular disease (OR:4.7; 95% CI 1.258-17600; P=0.013),chronic lung disease(OR: 14.5; CI 95% 1.835-115.999).The results of multivariate analysis of Adj Odd Ratio10.038 (95% CI 2.447 – 41.172; P<0.001)and the association with obesity with the Adj Odd Ratio 4.846 (95% CI 1.187 – 19.789; P=0.028). Conclusion: Hyperglycemia and obesity are risk factors for severe COVID-19.

show abstract

Incidence of Steroid-induced Diabetes in COVID-19 patients

Cited by 4 publications

References 12 publications

The prevalence of pre-diabetes and diabetes in people with and without past history of COVID-19 in northeastern Nigeria

The prevalence of pre-diabetes and diabetes in people with and without past history of COVID-19 in northeastern Nigeria

Hiperglicemia asociada al uso de corticoides en pacientes con COVID-19

Hyperglycemia and Obesity as Risk Factors for Severe Covid-19

Contact Info

Product

Resources

About